Good capitalists can agree that those who develop cutting-edge drugs deserve to be richly rewarded for their efforts. But then Americans must ask why they alone must bear the costs of bestowing the rewards.

Former U.S. drug executive Martin Shkreli, dubbed the “pharma bro” and vilified for raising the price of a lifesaving drug by 5,000 percent, was suspended by Twitter on Sunday for harassing a female journalist.

Calling Valeant a “drug company” is problematic because it’s not much into researching and developing new medications. “Bet on management, not on science,” its outgoing CEO, J. Michael Pearson, was fond of saying.